A 1-for-35 ratio is the governing math behind Tenon Medical's stock consolidation: 35 issued and outstanding common shares converted into one, effective 12:01 a.m. Eastern on August 10, 2026, the moment before Nasdaq Capital Market trading opened. Tenon Medical, Inc. (NASDAQ: TNON) disclosed the action through an 8-K filing, with stockholder approval secured at the annual meeting held July 23, 2026. The company's primary stated goal is to bring the per-share price above the $1.00 minimum average closing price Nasdaq requires for continued listing on the Nasdaq Capital Market.
Split mechanics and CUSIP change
Tenon's common stock opened August 10 on a split-adjusted basis under the unchanged ticker TNON. The CUSIP number changed to 88066N402. No fractional shares were issued. Any fractional entitlement rounds up to the next whole share. Vstock Transfer, LLC, the company's transfer agent, is acting as exchange agent for the transaction.
Shareholder steps
Stockholders holding shares in book-entry form or through a bank, broker, or nominee do not need to take any action. Certificate holders will receive a letter of transmittal from Vstock with instructions for surrendering pre-split certificates; Tenon specified that shareholders should not send in certificates until that letter arrives. Post-split shares for certificate holders will be delivered in book-entry form, accompanied by a Vstock ownership statement, unless a shareholder specifically requests a new paper certificate or holds restricted shares.
About Tenon Medical
Tenon Medical is a Los Gatos, California medical device company focused on sacro-pelvic disorders, incorporated in Delaware in 2012. It offers two SI joint systems: the Catamaran SI Joint Fusion System, nationally launched in October 2022, and the SImmetry+ SI Joint Fusion System, obtained through the August 2025 acquisition of substantially all assets of SiVantage, Inc. and SIMPL Medical, LLC. The company operates across three commercial segments: primary SI joint procedures, revision of failed SI joint implants, and SI joint fusion as an adjunct to spine fusion constructs. The definitive proxy statement covering the reverse split, filed with the SEC on June 23, 2026, is available at www.sec.gov and at ir.tenonmed.com.